Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Flygt, Hjalmar
22  Ergebnisse:
Personensuche X
?
1

Treatment-free remission after a second TKI discontinuation..:

Flygt, Hjalmar ; Söderlund, Stina ; Richter, Johan...
Leukemia.  38 (2024)  4 - p. 781-787 , 2024
Link: https://doi.org/10.1038/..
 
?
2

Correction: Treatment-free remission after a second TKI dis..:

Flygt, Hjalmar ; Söderlund, Stina ; Richter, Johan...
Leukemia.  38 (2024)  4 - p. 925-925 , 2024
Link: https://doi.org/10.1038/..
 
?
3

The impact of Covid-19 in patients with chronic myeloid leu..:

Dahlén, Torsten ; Flygt, Hjalmar ; Lübking, Anna...
Leukemia.  37 (2023)  5 - p. 1156-1159 , 2023
Link: https://doi.org/10.1038/..
 
?
4

The impact of Covid-19 in patients with chronic myeloid leu..:

Dahlen, Torsten ; Flygt, Hjalmar ; Lubking, Anna...
Leukemia, 0887-6924, 2023.  , 2023
Link: http://urn.kb.se/resolve..
 
?
5

The impact of Covid-19 in patients with chronic myeloid leu..:

Dahlén, Torsten ; Flygt, Hjalmar ; Lübking, Anna...
Leukemia, 0887-6924, 2023, 37, s. 1156-1159.  , 2023
Link: http://urn.kb.se/resolve..
 
?
6

The impact of Covid-19 in patients with chronic myeloid leu..:

Dahlén, Torsten ; Flygt, Hjalmar ; Lübking, Anna...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10088575/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
7

Adverse outcomes in chronic myeloid leukemia patients treat..:

Dahlén, Torsten ; Edgren, Gustaf ; Ljungman, Per...
American Journal of Hematology.  97 (2022)  4 - p. 421-430 , 2022
Link: https://doi.org/10.1002/..
 
?
8

Adverse outcomes in chronic myeloid leukemia patients treat..:

Dahlén, Torsten ; Edgren, Gustaf ; Ljungman, Per...
American Journal of Hematology, 0361-8609, 2022, 97:4, s. 421-430.  , 2022
Link: http://urn.kb.se/resolve..
 
?
9

Adverse outcomes in chronic myeloid leukemia patients treat..:

Dahlén, Torsten ; Edgren, Gustaf ; Ljungman, Per...
American Journal of Hematology, 0361-8609, 2022, 97:4, s. 421-430.  , 2022
Link: http://urn.kb.se/resolve..
 
?
10

Long-term tolerability and efficacy after initial PegIFN-al..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
10.1111/ejh.13699.  , 2022
Link: http://hdl.handle.net/10..
 
?
11

Adverse outcomes in chronic myeloid leukemia patients treat..:

Dahlén, Torsten ; Edgren, Gustaf ; Ljungman, Per...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306877/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
12

Adverse outcomes in chronic myeloid leukemia patients treat..:

Dahlen, Torsten ; Edgren, Gustaf ; Ljungman, Per...
American Journal of Hematology, 0361-8609, 2022, 97:4, s. 421-430.  , 2022
Link: http://urn.kb.se/resolve..
 
?
13

Successful tyrosine kinase inhibitor discontinuation outsid..:

Flygt, Hjalmar ; Sandin, Fredrik ; Dahlén, Torsten...
British Journal of Haematology.  193 (2021)  5 - p. 915-921 , 2021
Link: https://doi.org/10.1111/..
 
?
14

Long‐term tolerability and efficacy after initial PegIFN‐α ..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
European Journal of Haematology.  107 (2021)  6 - p. 617-623 , 2021
Link: https://doi.org/10.1111/..
 
?
15

Successful tyrosine kinase inhibitor discontinuation outsid..:

Flygt, Hjalmar ; Sandin, Fredrik ; Dahlén, Torsten...
British Journal of Haematology, 0007-1048, 2021, 193:5, s. 915-921.  , 2021
Link: http://urn.kb.se/resolve..
 
1-15